Statement: Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis.
Primary_evidence: INTERVENTION 1:    Letrozole and Imatinib Mesylate   Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle.